Market news

I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Mirum Pharmaceuticals (MIRM).

The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.

Mirum Pharmaceuticals is technically oversold but is likely to have more major drug pipeline catalysts occur in the coming months. Click for more on MIRM.

Mirum nears an FOP launch Sept 26; PROGRESS data, small market risks, and brelovitug Phase 3 catalysts ahead. See here for more on MIRM stock.

FOSTER CITY, Calif., September 14, 2026--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., September 08, 2026--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FOSTER CITY, Calif., September 02, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals reported second-quarter 2026 results showing a net loss of US$67.23 million (US$1.06 per share) and a six-month net loss of US$857.38 million (US$14.03 per share), while also updating investors on commercial progress and pipeline developments. Despite the very large year-on-year increase in net loss, Mirum raised its 2026 net product sales guidance, highlighted breakthrough therapy designation for volixibat, and outlined the potential US launch timing for Zilurgisertib,...

Motley Fool Press Release.

FOSTER CITY, Calif., August 11, 2026--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Insmed stock led a biotech rally Thursday, catapulting more than 30% on solid second-quarter sales for its new lung disease drug.

The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program.

The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Mirum Pharmaceuticals (MIRM) reported fiscal Q2 loss late Wednesday of $1.06 per diluted share, wide

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -3.90% and +6.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FOSTER CITY, Calif., August 05, 2026--Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfo

FOSTER CITY, Calif., July 29, 2026--Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026